Back to Search
BARBARA GITLITZ, M.D.
Medical Oncology Physician
NPI: 1467488015Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
G70326(CA)
Research & Publications (20)
Cytokine-based therapy for metastatic renal cell cancer.
PMID 12953757·Urol Clin North Am·2003
6-review
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
PMID 14584068·Cancer·2003
3-trial
Cell, gene and vaccine based strategies in kidney cancer.
PMID 14650833·Cancer Treat Res·2003
6-review
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
PMID 19096314·J Thorac Oncol·2009
3-trial
Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
PMID 15128982·Radiology·2004
8-other
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
PMID 12771723·J Urol·2003
8-other
Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.
PMID 12576811·J Urol·2003
8-other
Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.
PMID 12597937·Urology·2003
4-observational
Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
PMID 12784334·Cancer·2003
8-other
Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients.
PMID 12949803·Int J Cancer·2003
3-trial
Mathematical model to predict individual survival for patients with renal cell carcinoma.
PMID 11870181·J Clin Oncol·2002
8-other
Collecting duct renal cell carcinoma: clinical study of a rare tumor.
PMID 11743278·J Urol·2002
8-other
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.
PMID 11435822·J Urol·2001
8-other
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
PMID 11691814·Cancer Res·2001
7-preclinical
Improved prognostication of renal cell carcinoma using an integrated staging system.
PMID 11250993·J Clin Oncol·2001
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1441 EASTLAKE AVE
LOS ANGELES, CA 90089 - Phone
- (323) 865-3105
Quick Facts
- NPI
- 1467488015
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile